Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$25.69 USD

25.69
13,642,409

+0.29 (1.14%)

Updated Apr 29, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PFE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pfizer Inc. [PFE]

Reports for Purchase

Showing records 521 - 540 ( 554 total )

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 521

12/13/2011

Company Report

Pages: 3

Dividend Increase, Share Repurchase, Management Changes

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 10.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 522

12/02/2011

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 523

11/15/2011

Company Report

Pages: 13

Overall near term outlook still remains quite encouraging despite Lipitor’s patent expiry.

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 524

11/11/2011

Company Report

Pages: 11

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 525

11/02/2011

Company Report

Pages: 11

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 526

11/01/2011

Company Report

Pages: 9

3Q Revenue and EPS Ahead of Expectations. Lipitor Patent Expiration Approaching

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 527

11/01/2011

Industry Report

Pages: 17

BABY FOOD REVISITED

Provider: G.RESEARCH, LLC

Analyst: GABELLI J

Price: 50.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 528

09/15/2011

Company Report

Pages: 15

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 529

08/23/2011

Company Report

Pages: 13

Management reiterates guidance for CY11 & CY12........

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 530

08/02/2011

Company Report

Pages: 11

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 531

07/14/2011

Daily Note

Pages: 2

MODEL STOCK PORTFOLIO -CONSERVATIVE GROWTH

Provider: J.J.B. Hilliard, W.L. Lyons

Price: 10.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 532

06/22/2011

Industry Report

Pages: 28

Pharmaceuticals Food For Thought

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 533

06/21/2011

Industry Report

Pages: 25

Upgrading Global Pharma sector to ‘Moderate Outperform’

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 75.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 534

05/17/2011

Company Report

Pages: 15

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 535

05/05/2011

Company Report

Pages: 13

Management reiterates earlier guidance for CY11 & CY12

Provider: FIRST GLOBAL

Analyst: THOMAS K

Price: 50.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 536

05/04/2011

Company Report

Pages: 11

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 537

05/03/2011

Company Report

Pages: 8

First Quarter 2011 Revenue About Even. Non-GAAP EPS Exceeded Consensus Expectations.

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 538

04/13/2011

Industry Report

Pages: 7

Monthly Rx Highlights - March 2011

Provider: DUNCAN-WILLIAMS, INC.

Analyst: RIVKIND I

Price: 25.00

Research Provided by a Third Party

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 539

04/06/2011

Company Report

Pages: 10

Price: 24.95

Company: Pfizer Inc.

Industry: Large Cap Pharmaceuticals

Record: 540

03/16/2011

Industry Report

Pages: 7

Monthly Rx Highlights - February 2011

Provider: DUNCAN-WILLIAMS, INC.

Analyst: RIVKIND I

Price: 25.00

Research Provided by a Third Party